BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 06, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/3 cls
Acadia (ACAD) Piper Jaffray Edward Tenthoff Price target Market outperform 3% $15.23
Tenthoff raised his target to $21 from $13. He expects data this month from a Phase II trial of ACP-103 to treat Parkinson's disease (PD), and expects ACAD to start Phase III testing this year.
Adolor (ADLR) WR Hambrecht Patrick Flanigan III Price target Buy 1% $26.85
Flanigan raised his target to $35 from $24. He expects FDA approval for Entereg in post-operative ileus (POI) and positive Phase III data in chronic opioid-induced bowel dysfunction this year. The mu opioid receptor antagonist is partnered with GlaxoSmithKline (LSE:GSK; GSK).
Alkermes (ALKS) Pacific Growth Patricia Bank Downgrade Neutral (from buy) 7% $25.74
Bank's downgrade was due to "recent share appreciation," which she said puts the stock within 10% of...

Read the full 859 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >